Literature DB >> 30760083

Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact.

Martin Porsch1,2,3, Esra Özdemir4, Martin Wisniewski4, Sebastian Graf1, Fabian Bull1,2,3, Katrin Hoffmann2, Atanas Ignatov5, Johannes Haybaeck4,6,7, Ivo Grosse1,3, Thomas Kalinski4, Norbert Nass4.   

Abstract

Acquired tamoxifen resistance is a persistent problem for the treatment of estrogen receptor positive, premenopausal breast cancer patients and predictive biomarkers are still elusive. We here analyzed gene expression changes in a cellular model to identify early and late changes upon tamoxifen exposure and thereby novel prognostic biomarkers. Estrogen receptor positive MCF-7 cells were incubated with 4OH-tamoxifen (10 nM) and gene expression analyzed by array hybridization during 12 weeks. Array results were confirmed by nCounter- and qRT-PCR technique. Pathway enrichment analysis revealed that early responses concerned mainly amine synthesis and NRF2-related signaling and evolved into a stable gene expression pattern within 4 weeks characterized by changes in glucuronidation-, estrogen metabolism-, nuclear receptor- and interferon signaling pathways. As a large number of long non coding RNAs was subject to regulation, we investigated 5 of these (linc01213, linc00632 linc0992, LOC101929547 and XR_133213) in more detail. From these, only linc01213 was upregulated but all were less abundant in estrogen-receptor negative cell lines (MDA-MB 231, SKBR-3 and UACC3199). In a web-based survival analysis linc01213 and linc00632 turned out to have prognostic impact. Linc01213 was investigated further by plasmid-mediated over-expression as well as siRNA down-regulation in MCF-7 cells. Nevertheless, this had no effect on proliferation or expression of tamoxifen regulated genes, but migration was increased. In conclusion, the cellular model identified a set of lincRNAs with prognostic relevance for breast cancer. One of these, linc01213 although regulated by 4OH-tamoxifen, is not a central regulator of tamoxifen adaption, but interferes with the regulation of migration.

Entities:  

Keywords:  Breast cancer; biomarker; gene expression; long-non coding RNAs; tamoxifen

Mesh:

Substances:

Year:  2019        PMID: 30760083      PMCID: PMC6546408          DOI: 10.1080/15476286.2019.1581597

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  68 in total

1.  A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling.

Authors:  Zhaoyi Wang; Xintian Zhang; Peng Shen; Brian W Loggie; Yunchao Chang; Thomas F Deuel
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

Review 2.  Mechanisms of tamoxifen resistance.

Authors:  Alistair Ring; Mitch Dowsett
Journal:  Endocr Relat Cancer       Date:  2004-12       Impact factor: 5.678

3.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

4.  Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.

Authors:  K A Lewis; P C Gray; A L Blount; L A MacConell; E Wiater; L M Bilezikjian; W Vale
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

5.  Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM.

Authors:  Michael Becker; Anette Sommer; Jörn R Krätzschmar; Henrik Seidel; Hans-Dieter Pohlenz; Iduna Fichtner
Journal:  Mol Cancer Ther       Date:  2005-01       Impact factor: 6.261

6.  Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells.

Authors:  Shubin Sheng; Daniel H Barnett; Benita S Katzenellenbogen
Journal:  Mol Cell Endocrinol       Date:  2008-10-04       Impact factor: 4.102

7.  Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.

Authors:  Elton R Kisanga; Jennifer Gjerde; Aliana Guerrieri-Gonzaga; Francesca Pigatto; Adriana Pesci-Feltri; Chris Robertson; Davide Serrano; Giuseppe Pelosi; Andrea Decensi; Ernst A Lien
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

Review 8.  Understanding and treating triple-negative breast cancer.

Authors:  Carey Anders; Lisa A Carey
Journal:  Oncology (Williston Park)       Date:  2008-10       Impact factor: 2.990

9.  Virtual and biomolecular screening converge on a selective agonist for GPR30.

Authors:  Cristian G Bologa; Chetana M Revankar; Susan M Young; Bruce S Edwards; Jeffrey B Arterburn; Alexander S Kiselyov; Matthew A Parker; Sergey E Tkachenko; Nikolay P Savchuck; Larry A Sklar; Tudor I Oprea; Eric R Prossnitz
Journal:  Nat Chem Biol       Date:  2006-03-05       Impact factor: 15.040

10.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

View more
  5 in total

1.  Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development.

Authors:  Stephen F Madden; Mattia Cremona; Angela M Farrelly; Weng Hei Low; Jean McBryan
Journal:  Cancer Gene Ther       Date:  2022-10-20       Impact factor: 5.854

2.  Exosomal LINC01213 Plays a Role in the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manners.

Authors:  Zhuifeng Guo; Xuwei Lu; Fan Yang; Chang He; Liang Qin; Ning Yang; Conghui Han; Jiawen Wu
Journal:  J Oncol       Date:  2022-03-10       Impact factor: 4.375

3.  BCL3 expression is strongly associated with the occurrence of breast cancer relapse under tamoxifen treatment in a retrospective cohort study.

Authors:  Piotr Czapiewski; Maximilian Cornelius; Roland Hartig; Thomas Kalinski; Johannes Haybaeck; Angela Dittmer; Jürgen Dittmer; Atanas Ignatov; Norbert Nass
Journal:  Virchows Arch       Date:  2022-01-12       Impact factor: 4.535

4.  Relationship of micro-RNA, mRNA and eIF Expression in Tamoxifen-Adapted MCF-7 Breast Cancer Cells: Impact of miR-1972 on Gene Expression, Proliferation and Migration.

Authors:  Akhil Behringer; Darko Stoimenovski; Martin Porsch; Katrin Hoffmann; Gerhard Behre; Ivo Grosse; Thomas Kalinski; Johannes Haybaeck; Norbert Nass
Journal:  Biomolecules       Date:  2022-06-29

5.  Construction and Analysis of a Long Non-Coding RNA-Associated Competing Endogenous RNA Network Identified Potential Prognostic Biomarkers in Luminal Breast Cancer.

Authors:  Zhou Jiang; Pu Cheng; Biyuan Luo; Jian Huang
Journal:  Onco Targets Ther       Date:  2020-05-18       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.